ArticleBMC infectious diseases2025
Cross-reactivity IgG, viral load, severity and vaccination outcome as an approach for understanding humoral immune response against SARS-CoV-2.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundSerological evaluation plays a crucial role in understanding cross-reactivity, the prevalence of infection, immune response in COVID-19 disease, asymptomatic infections, and vaccine effectiveness.
methodsRecombinant spike (rS) and Nucleocapsid (rN) proteins from SARS-CoV-2 were used to determine IgG antibodies (Abs) in serum samples obtained from Mexican adults and paediatrics before and during the pandemic by enzyme-linked immunosorbent assay.
resultsHuman sera from 2003 to 2016 showed higher levels of cross seropositivity (54.5‒75%) against rS and rN. In serum samples from adult patients with COVID-19, the reactivity intensity (RI) depended on the severity of the disease, whereas in convalescent paediatric patients with COVID-19, SARS-CoV-2 viral load depended on sex and comorbidities. Regarding vaccine effectiveness monitoring, an increased RI of anti-rS IgG was observed in people vaccinated against COVID-19 who had a natural infection with SARS-CoV-2. During the vaccination scheme, an increase in IgG Abs level was observed with the second dose, whereas a decrease was observed after six months of vaccination. Vaccine boosters increased RI in either homologous/heterologous administration of mRNA and non-replicating viral vector vaccines.
conclusionsEpidemiological outbreaks and the circulation of non-SARS-CoV-2 coronaviruses may contribute to the primary causes of the observed cross-reactions in antibodies. Furthermore, factors such as viral load and disease severity in infected patients, prior illnesses, the dosage of vaccine and booster shots, and the type of vaccine used in COVID-19-vaccinated individuals may also influence the increase in IgG antibodies. Assessing the antibody-based humoral immune response in serum samples collected before and during an outbreak or pandemic could aid in comprehending emerging and re-emerging diseases and developing effective preventive strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.